Download PDF
Arzneimittelforschung 2009; 59(1): 21-27
DOI: 10.1055/s-0031-1296360
Antiosteoporotics · Chondroprotective Drugs
Editio Cantor Verlag Aulendorf (Germany)

Analysis and Pharmacokinetics of the New Synthetic Azulene Antiosteoporotic Compound S001-281 and its Sulphoxide Metabolite in Rats Using a LC-UV method

A pilot study
Rajendra Pratap Singh
1   Pharmacokinetics and Metabolism Division, Central Drug Research Institute, Lucknow, (India)
2   Department of Pharmacology, Cadila Pharmaceuticals limited, Ahmedabad, (India)
,
Ram Chandra Gupta
1   Pharmacokinetics and Metabolism Division, Central Drug Research Institute, Lucknow, (India)
,
Kumar Girish Jain
1   Pharmacokinetics and Metabolism Division, Central Drug Research Institute, Lucknow, (India)
,
Shio Kumar Singh
1   Pharmacokinetics and Metabolism Division, Central Drug Research Institute, Lucknow, (India)
› Author Affiliations
Further Information

Publication History

Publication Date:
14 December 2011 (online)

    Permissions and Reprints

Abstract

In the present study an accurate and precise HPLC-UV method in rat plasma has been developed and validated for simultaneous determination of S001-281, a new synthetic azulene antiosteoporotic compound, and its sulfoxide metabolite. Separation was achieved using a reversed phase column with a mobile phase comprising acetonitrile and ammonium acetate buffer pH 6 (gradient elution) using a UV detector set at a wavelength of 308 nm. The method, applicable to 200 µL plasma, involved double extraction of the samples with diethyl ether. The absolute recovery of both the analytes was > 90%. The method was sensitive with a limit of quantitation of 25 ng/mL in rat plasma. Precision and accuracy were within the acceptable limits as indicated by bias varying from −0.11 to 16.93% and precision values ranged from 2.0 to 12.7%. Moreover, S001-281 was stable in rat plasma up to 30 days of storage at – 60 °C and after being subjected to three freeze/thaw cycles. The method was applied to generate the pharmacokinetics of S001-281 in rats after single dose oral administration.

Key words

Antiosteoporotics - Azulene derivative, biomatrices, pharmacokinetics, rat plasma, reversed phase HPLC - S001-281
 

  • References

  • 1 Roberts SA. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xeno-biotica. 2001; 31: 557-89
    CrossrefPubMedGoogle Scholar
  • 2 Keseru GM, Makara GM. Hit discovery and hit-to-lead approaches. Drug Discovery Today. 2006; 11: 741-8
    CrossrefPubMedGoogle Scholar
  • 3 Kassel DB. Applications of high-throughput ADME in drug discovery. Curr Opin Chem. Biol. 2004; 8: 339-45
    CrossrefPubMedGoogle Scholar
  • 4 Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006; 194: S3-11
    CrossrefPubMedGoogle Scholar
  • 5 Poole KES, Compston KE. Osteoporosis and its management. BMJ. 2006; 333 (7581) 1251-6
    CrossrefPubMedGoogle Scholar
  • 6 Report of a WHO Scientific Group. Prevention and management of Osteoporosis. WHO Technical Report Series, No 921, 2003.
    PubMed
  • 7 Guidelines for preclinical evaluation and clinical trials in osteoporosis. Geneva: WHO; 1998. p. 59.
    PubMed
  • 8 Shah VP, Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ et al. Bioanalytical method validation. A revisit with a decade of progress. Pharm Res. 2000; 17: 1551-7
    CrossrefPubMedGoogle Scholar
  • 9 Nagaraj NV, Paliwal JK, Gupta RC. Choosing the calibration model in assay validation. J Pharm Biomed Anal. 1999; 20: 433-8
    CrossrefPubMedGoogle Scholar
  • 10 Rajanikanth M, Gupta RC. LC fluorescence method for multiple synthetic compounds to rapidly create in vivo pharmacokinetic database utilizing ‘N-in-One’ dosing. J Pharm Biomed Anal. 2001; 26: 519-30
    CrossrefPubMedGoogle Scholar
  • 11 Lai J, Mehrotra N, Gupta RC. Analysis and pharmacokinetics of bulaquine and its major metabolite primaquine in rabbits using an LC-UV method. A pilot study. J Pharm Biomed Anal. 2003; 32: 141-50
    CrossrefPubMedGoogle Scholar